Use of a Pediatric Obesity Fall-risk Scale (POFS) in 301 hospitalized obese children and adolescents

Sofia Tamini1, Sabrina Cicolini1, Anna Porcu2

  • 1Experimental Laboratory for Auxo-Endocrinological Research, Istituto Auxologico Italiano, IRCCS, Verbania, Italy.

Insights

The Pediatric Obesity Fall-risk Scale (POFS) helps identify hospitalized obese children at high risk of falls, though BMI was not a differentiating factor. This tool aids in targeted interventions for fall prevention in pediatric patients.

Area of Science:

  • Pediatrics
  • Clinical Safety
  • Obesity Research

Background:

  • Falls pose a significant safety risk for hospitalized patients.
  • Evidence on fall risk in obese pediatric patients is limited.
  • Obese children may have unique fall risk factors requiring specific assessment tools.

Purpose of the Study:

  • To determine if the Pediatric Obesity Fall-risk Scale (POFS) can differentiate between high and low fall risk in hospitalized obese children.
  • To evaluate the sensitivity and specificity of the POFS.
  • To analyze the relationship between POFS risk factors and actual falling events.

Main Methods:

  • A 12-month study involving 301 hospitalized obese children and adolescents in a weight reduction program.
  • The Pediatric Obesity Fall-risk Scale (POFS) components included age, fall history, BMI-SDS, and equilibrium.
  • Fall incidence was tracked, and fallers were compared to non-fallers.

Main Results:

  • 14.6% of patients experienced falls; fall rates were 5.33 and 4.36 per 1000 patient-days.
  • Fallers were younger, shorter, and lighter than non-fallers; BMI and BMI-SDS did not differ.
  • POFS identified high-risk (85) and low-risk (216) groups; high-risk patients were younger, shorter, and lighter.
  • POFS sensitivity was 61.4%, specificity 77.4%, PPV 31.8%, NPV 92.1%.

Conclusions:

  • The POFS is a valuable tool for identifying hospitalized obese pediatric patients at high risk of falls.
  • Younger age, shorter stature, and lower weight were associated with higher fall risk.
  • Targeted interventions are necessary for high-risk pediatric patients to prevent falls.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
71
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
81
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
79
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
64
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
76
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
109